title: Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma.
abstract: A 68-year-old man presented with general fatigue, increasing adynamia, weakness, vertigo and recurrent syncope. Six weeks earlier the diagnosis of a macroprolactinoma had been established based on a greatly elevated prolactin concentration (161 170 micro U/l) and MR-evidence of a 3.5 cm measuring pituitary mass. The patient had been started on cabergoline (1.5 mg weekly). Orthostatic hypotension due to the dopamine agonist was considered very likely and carbergoline therapy was stopped. However, there was no relief of the symptoms and further syncopes followed. Testing of blood pressure and heart rate regulation, selective testing of postganglionic cardiac neurons with [ 123 J] metaiodobenzylguanidine scintigraphy provided evidence of grossly impaired neurogenic cardiovascular regulation due to failure of postganglionic efferent sympathetic activity. This is characteristic for pure autonomic failure. The patient was treated symptomatically with high fluid intake, compression stockings, fludrohydrocortisone (0.1 mg o.d.s.), piroxicam (20 mg o.d.s.) and etilephrin (10 mg q.d.s.), which enabled him to cope with daily activities without syncope. This case shows that vertigo in a patient with macroprolactinoma is not always related to drug therapy but may be related to other causes.
authors.affiliation: Department of Internal Medicine II, University of Freiburg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Seiler
authors.forename: S
authors.initials: S
authors.lastname: Braune
authors.forename: K
authors.initials: K
authors.lastname: Borm
authors.forename: C
authors.initials: C
authors.lastname: Magerkurth
authors.forename: J
authors.initials: J
authors.lastname: Talazko
authors.forename: T
authors.initials: T
authors.lastname: Peters
authors.forename: M
authors.initials: M
authors.lastname: Reincke
mesh_terms: D000322:Adrenergic Agonists / Q000627:therapeutic use; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001342:Autonomic Nervous System Diseases / Q000209:etiology*; D001794:Blood Pressure; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000494:pharmacology*; D007172:Erectile Dysfunction / Q000209:etiology; D005039:Etilefrine / Q000627:therapeutic use*; D005438:Fludrocortisone / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D010894:Piroxicam / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D015175:Prolactinoma / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D014636:Valsalva Maneuver; D014717:Vertigo / Q000139:chemically induced / Q000209:etiology*
chemical_list: D000322:Adrenergic Agonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D018491:Dopamine Agonists; D006728:Hormones; D010894:Piroxicam; D005438:Fludrocortisone; D005039:Etilefrine